Inhalational nitric oxide in pulmonary parenchymal and vascular disease

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 6, 1996, Pages 530-539

  Cornfield, David N ^a   Abman, Steven H ^b  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030174841     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90143-2     Document Type: Review

References (64)

1. West JB, Wagner PD. Ventilation-perfusion relationships. In: Crystal RG, West JB. The lung: scientific foundations. New York: Raven Press Ltd., 1991:1289-305.
2. Calvin JE, Baer RW, Glantz SA. Pulmonary artery constriction produces a greater right ventricular afterload than lung microvascular injury in the open chest dog. Circ Res 1985; 56:40-56.
3. Sibbald WJ, Driedger AA, Myers ML, Short AI, Wells GH. Biventricular function in the adult respiratory distress syndrome. Chest 1983;84:126-34.
4. Radermacher P, Santak P, Becker H, Falke KJ. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary wedge pressure but worsen V/Q distribution in patients with adult respiratory distress syndrome. Anesthesiology 1989;70:601-9.
5. Melot C, Lejeunne P, Leeman M, Moraine JJ, Naeije R. Prostaglandin E1 in the adult respiratory distress syndrome: benefit for pulmonary hypertension and cost pulmonary gas exchange. Am Rev Respir Dis 1989;139:106-10.
6. Zapol WM, Snyder MT. Pulmonary arterial hypertension in severe acute respiratory failure. N Engl J Med 1977;296:476-80.
7. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-6.
8. Moncada S, Palmer RMJ, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988;12:365-72.
9. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
10. Mitchell JA, Hecker M, Vane JR. The generation of L-arginine in endothelial cells is linked to the release of endothelium-derived relaxing factor. Eur J Pharmacol 1990;176: 253-4.
11. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin requiring enzyme. Proc Natl Acad Sci USA 1990; 87:682-5.
12. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977;74:3203-7.
13. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosamine. The Journal of Cyclic Nucleotide Protein Phosphorylation Research 1979;5:211-44.
14. Archer SL, Huang J, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by cGMP-kinase-dependent activation of a charybdotoxin-sensitive potassium channel. Proc Natl Acad Sci USA 1994;91:7583-7.
15. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle cells. Nature 1994;368: 850-3.
16. Pepke-Zaba J, Higenbotam T, Dinh Xuan A, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338: 1173-4.
17. Frostell C, Fratacci M-D, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83: 2038-47.
18. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
19. Roberts J, Polaner D, Lang P, Zapol W. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-9.
20. Rossaint R, Falke KF, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
21. Young CL. Solubility of nitric oxide in aqueous and nonaqueous solvents. Solubility Data Series 1981;8:336-51.
22. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 1981;14:351-8.
23. Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe respiratory distress syndrome. Anesthesiology 1994;80:761-70.
24. Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993;123:103-8.
25. Miller OI, Celermajer DS, Deanfleld JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994;108:487-94.
26. Adnot S, Kouyoumdjian C, Defouilloy C, et al. Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1993;148:310-6.
27. Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VWM. cGMP and nitric oxide modulate thrombin-induced endothelial permeability in human aortic and umbilical vein endothelial cells. Circ Res 1995;76:199-208.
28. Meyrick B, Reid L. Pulmonary hypertension: anatomic and physiologic correlates. In: Matthay N, Dantzker R. Philadelphia: WB Saunders, 1983:199-217.
29. Giaid A, Saleh DS. Reduced expression of endothelial nitric oxide in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
30. Kouyoumdjian C, Adnot S, Levame M, Eddahibi S, Bousbaa H, Raffestin B. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 1994;94:578-84.
31. Ivy DD, Wiggins JW, Badesch DB, Kinsella JP, Kelminson LL, Abman SH. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension. Am J Cardiol 1994;74:414-6.
32. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 1993;18:195-9.
33. Radi R, Beckman JS, Bush KM, Freeman B. Peroxynitrite-induced membrane lipid peroxidation. Arch Biochem Biophys 1991;288:481-7.
34. Haddad I, Ischiropoulos H, Holm B, Beckman J, Baker J, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993;265:L555-64.
35. Wink D, Hanbauer I, Krishna M. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1993;90:9813-7.
36. Jobe A. Surfactant in the perinatal period. Early Human Development 1992;29:57-62.
37. Evans N, Archer L. Doppler assesment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child 1991;67:366-73.
38. Walther F, Boys R, Hunter S, Hey E. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992;90:899-904.
39. Halbower AC, Tuder RM, Franklin WA, Pollock JS, Forstermann U, Abman SH. Maturation-related changes in endothelial nitric oxide synthase immunolocalization in developing ovine lung. Am J Physiol 1994;267:L585-91.
40. Kinsella JP, Ivy DD, Abman SH. Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. Am J Physiol 1994;267:H1955-61.
41. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res 1994;36:402-8.
42. Abman SH, Kinsella JP, Schaffer M, Wilkening R. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993;92:606-9.
43. Peliowski A, Finer NN, Etches P, Tierney A, Ryan C. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 1995;126:450-3.
44. Stenmark K, Abman SH, Accurso FJ. Etiologic mechanisms in peristent pulmonary hypertension of the newborn. In: Weir E, Reeves J. Pulmonary vascular physiology and pathophysiology. New York: Marcel Dekker, 1989:355-402.
45. Stevenson DK, Kasting DS, Darnall RA. Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazaline. J Pediatr 1979;95:595-9.
46. Finer N, Etches P, Kamstra B, Tierney A, Peliowski A, Ryan C. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994;124:302-8.
47. Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995;126:853-64.
48. Rabinovitch M. Structure and function of the pulmonary vascular bed: an update. Cardiol Clin 1989;7:895-914.
49. Turner-Gomes SO, Andrew M, Coles J, Trusler GA, Williams WG, Rabinovitch M. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992;103:87-97.
50. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in padiatric patients. Br Heart J 1995;73:65-8.
51. Roberts JDJ, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-53.
52. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88:2128-38.
53. Winberg P, Lundell BP, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994; 71:282-6.
54. Journois D, Pouard P, Mauriat P, Malhere T, Vouhe P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994;107:1129-35.
55. Rabinovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986;55:632-53.
56. Celermajer DS, Dollery C, Burch M, Deanfield JE. The role of endothelium in the maintenance of low pulmonary vascular tone in normal children. Circulation 1994; 89:2041-4.
57. Nichols D, McCloskey J, Rogers M. Adult respiratory distress syndrome. In: Rogers M. Textbook of pediatric intensive care. Baltimore: Williams and Wilkins, 1992:296-328.
58. Rinaldo J, Rogers R. Adult respiratory distress syndrome: changing concepts of lung injury and repair. N Engl J Med 1982;306:900-9.
59. Abman SH, Griebel JL, Parker DK, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994;124:881-8.
60. Gerlach H, Rossaint R, Pappert D, Falke KJ. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993; 23:499-502.
61. Hosenspred J, Novick R, Breen T, Daily B. The registry of the International Society for Heart and Lung Transplantation: eleventh official report. J Heart Lung Transplant 1994; 13:561-970.
62. Fullerton, DA, McIntyre RCJ, Mitchell MB, Campbell DN, Grover FL. Lung transplantation with cardiopulmonary bypass exaggerates pulmonary vasomotor dysfunction in the transplanted lung. J Thorac Cardiovasc Surg 1995;109:212-6.
63. Pinsky DJ, Naka Y, Chowdhury NC, et al. The nitric oxide/ cyclic GMP pathway in organ transplantation: critical role in successful transplantation. Proc Natl Acad Sci USA 1994;91: 12086-90.
64. Adatia I, Lillehei C, Arnold CH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-8.